Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
SERPINB5
REST API REST API
Homo sapiens
SERPINB5 is differentially expressed in 215 experiments: 144 organism parts: skin, cervix, ... (142 more);, 143 disease states: normal, colon carcinoma, ... (141 more);, 60 cell types 478 cell lines 18 compound treatments and 60 other conditions.
Synonyms maspin, PI5
Orthologs F6RYM0_CIOIN (Ciona intestinalis)   Serpinb5 (Rattus norvegicus)   F6VTS4_CIOIN (Ciona intestinalis)   E1BTE2_CHICK (Gallus gallus)   Serpinb5 (Mus musculus)   serpinb5 (Xenopus laevis)   A4FV69_BOVIN (Bos taurus)   SERPINB5 (Canis familiaris)   (Compare orthologs)
Gene Ontology Term protein binding, morphogenesis of an epithelium, serine-type endopeptidase inhibitor activity, cytoplasm, cellular component movement, negative regulation of endopeptidase activity, extracellular space, extracellular region, regulation of proteolysis, extracellular matrix organization, prostate gland morphogenesis, regulation of epithelial cell proliferation
InterPro Term Serpin_B9/Maspin, Sepin_dom
UniProt Accession P36952, C9JLM5
Search EB-eye ENSG00000206075
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-803, E-GEOD-15765, E-AFMX-5, E-MEXP-1251, E-MTAB-24, ... (20 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-17482, E-GEOD-5258, E-MEXP-1006, E-GEOD-19639, E-GEOD-18005, ... (33 experiments)

Factor Value U/D Experiments
MCF-7
1
3
E-GEOD-5823, E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
AGS
2
E-GEOD-15460, E-MTAB-37
DU145
2
E-GEOD-17482, E-GEOD-20089
HCC1937
2
E-MTAB-37, E-MTAB-62
MCF-10A
2
E-TABM-420, E-GEOD-14990
MDA-MB-231
2
E-TABM-420, E-MTAB-62
472 more value(s).


Cell type

studied in E-GEOD-21668, E-GEOD-19397, E-GEOD-3920, E-MEXP-66, E-GEOD-13987, ... (32 experiments)

Factor Value U/D Experiments
stromal cell
3
E-MEXP-2034, E-MEXP-1327, E-GEOD-1460
CD4+ T cell
2
E-AFMX-5, E-MTAB-25
CD8+ T cell
2
E-AFMX-5, E-MTAB-25
centrocyte
1
E-TABM-702
osteoblast
1
E-MEXP-1216
CD14+ monocyte
2
1
E-AFMX-5
54 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-6872, E-GEOD-2466, E-GEOD-1577, E-TABM-26, ... (38 experiments)

Factor Value U/D Experiments
colon carcinoma
4
E-MTAB-37, E-MTAB-57, E-GEOD-3726, E-MTAB-62
prostate carcinoma
4
E-TABM-26, E-MEXP-1327, E-GEOD-96, E-MTAB-62
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
AIDS-KS, HIV+, nodular (late) stage
2
E-MTAB-62, E-MEXP-66
acute lymphoblastic leukemia
2
E-MTAB-62, E-MTAB-37
cervical carcinoma
2
E-MTAB-62, E-MTAB-37
137 more value(s).


Compound treatment

studied in E-GEOD-1615, E-GEOD-571, E-GEOD-5824, E-GEOD-3720, E-GEOD-5339, ... (13 experiments)

Factor Value U/D Experiments
none
1
4
E-GEOD-412, E-GEOD-6431, E-GEOD-1615, E-GEOD-5824, E-GEOD-2803 ... (5 experiments)
phoshate buffered saline
1
E-GEOD-3720
nocodazole
1
E-GEOD-571
valproic acid
1
E-GEOD-1615
5-aza-2'-deoxycytidine + trichostatin A
1
1
E-MEXP-1269
dimethyl sulfoxide
6
1
E-GEOD-6932
12 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
thapsigargin
1
1
E-GEOD-19519
tunicamycin
1
1
E-GEOD-19519


Biosource provider
studied in E-MTAB-37, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19519, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19743, E-GEOD-7967, E-GEOD-2171, E-GEOD-21589, E-GEOD-16363, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-GEOD-19348, E-MEXP-1251, E-GEOD-2034, ... (7 experiments)

Clinical treatment
studied in E-GEOD-1743, E-GEOD-6532

coriell cell line repository identifier
studied in E-GEOD-19519

Developmental stage
studied in E-MEXP-2359, E-GEOD-4667, E-MEXP-958, E-MTAB-62

dfs time (months)
studied in E-GEOD-21653

Disease stage
studied in E-GEOD-7463

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-TABM-147, E-GEOD-21138, ... (6 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-3720

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532, E-GEOD-20194, E-GEOD-16716

family id
studied in E-GEOD-19519

Family relationship
studied in E-MEXP-1425

Genetic modification
studied in E-MTAB-108

Genotype
studied in E-GEOD-3494, E-GEOD-2466, E-GEOD-2292, E-TABM-868, E-TABM-601, ... (10 experiments)

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-TABM-263, E-MEXP-1220, E-MEXP-1446, E-GEOD-9764, E-TABM-440 ... (5 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-GEOD-21653, E-TABM-276

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2657, E-GEOD-1926, E-GEOD-10433, ... (32 experiments)

Infection
studied in E-GEOD-2405, E-GEOD-9723, E-GEOD-2077, E-GEOD-6802

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455, E-GEOD-9171

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-1801, E-TABM-84

Organism status
studied in E-GEOD-19188

Phenotype
studied in E-GEOD-21750, E-GEOD-17636

Progesterone receptor status
studied in E-GEOD-6532

Protocol type
studied in E-GEOD-3254, E-GEOD-19445, E-GEOD-19246, E-GEOD-1343

Replicate
studied in E-GEOD-10797, E-GEOD-10896

Rna integrity
studied in E-TABM-325

RNAi
studied in E-GEOD-12438, E-MEXP-1509, E-MEXP-548, E-GEOD-3697, E-MEXP-1315 ... (5 experiments)

Sample preparation
studied in E-GEOD-16728, E-GEOD-12710

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-19743, E-GEOD-21374, E-GEOD-17400

sbr grade
studied in E-GEOD-21653

Sex
studied in E-GEOD-2466, E-GEOD-7307

Stimulation
studied in E-GEOD-11428

Strain or line
studied in E-MEXP-1996

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

Test result
studied in E-TABM-276

Translocation cyclin group
studied in E-GEOD-2912

Treatment
studied in E-GEOD-16837, E-GEOD-19246

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-1561

Processing time: 0.414 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM